Conference paper
AN UPDATE ON: META-ANALYSIS OF MEDICAL AND NON-MEDICALTREATMENTS OF THE PRODROMAL PHASE OF PSYCHOTIC ILLNESS IN AT RISK MENTAL STATES
Gavin Deas
; University of Cambridge School of Clinical Medicine, Addenbrooke’s Hospital, Hills Road, Cambridge, UK
Christopher Kelly
; Centre for the Developing Brain, King's College London, London, UK ; Guy's and St Thomas' NHS Foundation Trust, UK
Andreas V. Hadjinicolaou
; Radcliffe Department of Medicine, University of Oxford , Oxford, UK ; Merton College, University of Oxford, Oxford, UK
Clare Holt
; Maudsley NHS Foundation Trust, UK
Mark Agius
; Clare College Cambridge, Cambridge, UK ; Bedfordshire Centre for Mental Health Research in Association with Cambridge University, Cambridge, UK ; Department of Psychiatry, University of Cambridge, Cambridge, UK
Rashid Zaman
; Bedfordshire Centre for Mental Health Research in Association with Cambridge University, Cambridge, UK ; Department of Psychiatry, University of Cambridge, Cambridge, UK
Abstract
Introduction: There are now many existing studies which assess the treatments available for ‘at risk mental states’, as patients
who are believed to be in the prodromal phase of psychotic illness are referred to. However, concerns regarding side effects of
possible treatments remain. We here conduct a meta-analysis of the studies available up to July 2016. The aim of this study is to
decide what would be the best treatment for ‘at high risk patients’.
Results: 18 studies were selected for inclusion; 12 showed significance, 5 did not and one tended towards significance. Both
antipsychotic medication and psychological intervention show mixed results with cognitive behavioral therapy and
olanzapine/amisulpride coming out on top. Omega 3 poly-unsaturated acid also shows promising and consistent results.
Discussion: Treatments appear promising but a balance needs to be kept between adverse events and effectiveness of preventing
psychosis.
Conclusion: It is necessary to search further for treatments in order to identify effective treatments with fewer adverse sideeffects
in this phase of psychotic illness.
Keywords
at risk mental state; anti-psychotics; anti-depressants; Omega 3 poly-unsaturated fatty acids; cognitive behaviour therapy
Hrčak ID:
264877
URI
Publication date:
30.8.2016.
Visits: 518 *